Mabthera 500 mg Concentrate for Solution for Infusion
Mabthera (Rituximab) 500mg is a concentrate for solution for infusion used to treat certain types of B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. It is a targeted monoclonal antibody that works by attacking CD20-positive B-cells. This medicine is given intravenously by a healthcare professional.
What it is
Rituximab is a CD20-directed cytolytic monoclonal antibody. It is a targeted therapy that attaches to a protein called CD20 found on the surface of certain immune cells (B-cells) and helps destroy them. This medicine is given as an intravenous infusion.
What it's used for
Mabthera is used to treat adult patients with: Non-Hodgkin's Lymphoma (NHL) that is low-grade or follicular, CD20-positive B-cell NHL, either alone or with chemotherapy, including as maintenance therapy after response; and chronic lymphocytic leukemia (CLL) in combination with chemotherapy. It is also indicated for previously untreated diffuse large B-cell NHL (data from openFDA/DailyMed).
Common side effects
Common side effects include infusion-related reactions (such as fever, chills, nausea, headache, and difficulty breathing during or shortly after the infusion). Other side effects may include infections, low blood cell counts, and tumor lysis syndrome. Serious but rare side effects include severe mucocutaneous reactions, hepatitis B reactivation, progressive multifocal leukoencephalopathy (PML), cardiovascular events, renal toxicity, and bowel obstruction or perforation. Seek immediate medical help if you experience severe symptoms.
Important cautions
Mabthera can cause serious infusion reactions which can be fatal. It must be given where resuscitation equipment is available. Hepatitis B reactivation has occurred; patients should be screened for hepatitis B before starting treatment. Progressive multifocal leukoencephalopathy (PML) has been reported. Tumor lysis syndrome may occur; aggressive hydration and monitoring of kidney function is required. Infections may occur; treatment should be withheld if serious infection develops. Discontinue if serious cardiac or renal events occur. Evaluate abdominal pain, vomiting, or related symptoms promptly. This list is not exhaustive; consult your doctor for complete safety information.
Frequently asked questions
What is Mabthera used for?
Mabthera is used to treat certain types of B-cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). It is often given alone or in combination with chemotherapy.
How is Mabthera given?
Mabthera is given as an intravenous (IV) infusion into a vein. It must be administered by a healthcare professional in a clinic or hospital setting. It is not injected as a simple shot.
What are the common side effects of Mabthera?
Common side effects include infusion-related reactions (fever, chills, nausea, headache, trouble breathing), infections, low blood counts, and tumor lysis syndrome. Serious side effects such as hepatitis B reactivation, PML, heart problems, kidney problems, and severe skin reactions can occur.
Can I buy Mabthera without a prescription in Nigeria?
According to the product information, Mabthera is an over-the-counter (OTC) medicine on Drugstore.ng. However, because it is a hospital-administered infusion, it must be given by a healthcare professional. You can order it on Drugstore.ng without a prescription, but it will require medical supervision for administration.
How is the dose of Mabthera determined?
The dose is typically calculated based on the patient's body surface area (measured in square metres) and the specific condition being treated. For example, in NHL the dose is 375 mg/m2, and in CLL it is 375 mg/m2 in the first cycle then 500 mg/m2 in subsequent cycles, given every 28 days with chemotherapy. Only your doctor can determine the correct dose and schedule for you.
This information is for general guidance only and is not medical advice. Please consult your physician or pharmacist before using any medication.
